Background: Vitamin D is a potent immune modulator associated with autoimmune diseases, predominantly Type 1 diabetes (T1D). Background: Vitamin D is a potent immune modulator and is associated with autoimmune diseases, predominantly Type 1 diabetes (T1D). The vitamin D status and its receptor gene polymorphisms in T1D are yet investigated in the South Indian population. Objective: The focus of the present study is to explore the significance of vitamin D levels and Vitamin D receptor (VDR) gene polymorphisms with the risk of T1D in the South Indian population. Methods: A total of 120 T1D patients and 214 unaffected first-degree relatives (FDRs) were enrolled in this study. Genotyping of VDR polymorphisms at four different loci (FokI- F/f, BsmI- B/b, TaqI- T/t, and ApaI- A/a) were assessed through the ARMS-PCR method. Serum vitamin D levels were measured in 98 T1D patients and 75 age and sex-matched siblings by the ELISA method. Results: Vitamin D deficiency (VDD) was observed in a higher proportion of T1D patients than in controls (52% vs. 32%; p<0.03). The frequency of FokI-FF genotype was significantly higher (OR=1.66; p<0.03) in T1D patients conferring susceptible association with the disease. Nevertheless, the increased frequency of heterozygous Ff genotype (OR=0.57; p<0.02) among controls may confer a protective association with T1D. Further, the TDT analysis revealed over the transmission of ApaI-A (T: U=15/5; p<0.006) and BsmI-B (T: U=17/5; p<0.01) alleles and under-transmission of BsmI-b/ApaI-a/TaqI-T haplotype (T: U=5.4/14.4; p=0.04) from parents to T1D patients. Conclusion: The present study concludes that VDD is one of the major contributing risk factors to T1D development in the South Indian population. Furthermore, the FokI-FF genotype, BsmI-B, and ApaI-A alleles are positively associated with T1D risk. Whereas, the FokI-Ff genotype and BsmI-b/ApaI-a/TaqI-T haplotype are negatively associated with the disease.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study approved by the Institutional Ethics Committees of Madurai Kamaraj University (MKU/IRB/11/11) and Govt. Rajaji Hospital (Ref. No. 23339/E4/3/10)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present work are contained in the manuscript